Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04045301
Other study ID # ITO-OMA-2018-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 11, 2019
Est. completion date March 2025

Study information

Verified date November 2023
Source St. Justine's Hospital
Contact Marie-Christine Auclair, B.Sc.N.
Phone (514) 345-4931
Email marie-christine.auclair.hsj@ssss.gouv.qc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be compared to placebo during an oral immunotherapy protocol for three simultaneous food allergens.


Description:

This is a phase 2b, multi-center randomized controlled trial comparing 2 doses of omalizumab to placebo in subjects 6 to 25 years old with multiple food allergies undergoing a symptom-driven multi-food OIT protocol. Subjects will undergo a screening period involving a DBPCFC to a mix of three allergens which will determine their eligibility and eliciting dose. Eligible subjects will be randomized to one of 2 omalizumab dosages or placebo at a ratio of 2:2:1 for a total period of 20 weeks. They will undergo initial food escalation (IFE) to determine their starting food treatment mix dose for three simultaneous food allergens after a pre-treatment period of 8 weeks with the study drug. Subjects will undergo up-dosing OIT visits at the clinic every two weeks, until a maintenance dose of 1500mg of protein (500mg per food) is reached (primary endpoint).


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date March 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 6 Years to 25 Years
Eligibility Inclusion criteria: 1. Male or female subjects 6 to 25 years old at screening visit. 2. History of IgE-mediated allergy to at least three foods within the following list: peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew, pistachio, almond, walnut and sesame. 3. Subjects currently following a strict avoidance of these three foods. 4. Positive SPT with a largest wheal diameter = 6 mm to all three foods. 5. Food-specific IgE level greater than 15 kU/L for all three foods 6. Positive DBPCFC to treatment food mix with an eliciting dose = 300 mg of total food protein. 7. Signed informed consent and assent. Exclusion criteria 1. Subjects reacting objectively to the placebo during the screening DBPCFC. 2. Severe asthma as defined by GINA 201948. 3. Active or past confirmed eosinophilic oesophagitis. 4. Subject currently under allergen immunotherapy. 5. Subject/parent with excessive anxiety unlikely to cope with study conditions as per investigator's opinion. 6. Subject/parent unwillingness to comply with study requirements. 7. Subject unwillingness to ingest a daily food dose of up to 1500 mg of allergen protein. 8. Inability to discontinue anti-histamine medication prior to study procedures. 9. Known allergy to omalizumab or its excipients. 10. Known allergy to components of the placebo food treatment mix that cannot be substituted without interfering with the blind (e.g.: dates, banana, chocolate syrup) 11. Use of immunosuppression or immunomodulatory drug (including omalizumab) or food oral immunotherapy or investigational treatment or procedure within 1 year. 12. Relative contraindication or inability to use epinephrine auto-injector. 13. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors. 14. Pregnancy or lactation for the duration of the study. 15. Any condition that is not compatible with the study treatment or procedures as per investigator judgment.

Study Design


Intervention

Biological:
Omalizumab 16mg/kg
Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
Omalizumab 8mg/kg
Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
Placebo
Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
Other:
Multi-food oral immunotherapy (OIT)
Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.

Locations

Country Name City State
Canada Centre Hospitalier Universitaire Sainte-Justine Montréal Quebec
Canada CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS) Sherbrooke Quebec
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (4)

Lead Sponsor Collaborator
Philippe Bégin Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Centre hospitalier de l'Université de Montréal (CHUM), The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the efficacy of omalizumab at decreasing time-to-maintenance during a symptom-driven multi-food OIT protocol. Time from IFE to target multi-food protein maintenance dose of 1500 mg of total food protein Assessed up to 52 weeks after IFE
Secondary Change in reactivity threshold to food treatment mix after pre-treatment with study drug. Measured as the amount of food allergen eliciting an objective allergic reaction on double-blinded oral food challenge or initial food escalation. Measured 8 weeks after starting investigational product
Secondary Average up-dosing speed while on study drug. Average of (log of escalation %)/(days since last escalation) for all escalation visits while on study drug From week 0 to week 12 post IFE
Secondary Mean cumulative function of allergic adverse events attributable to food dosing throughout the trial. AEs will be captured using the daily dosing diary throughout the trial, including during maintenance. Any systemic reaction having occurred since the last visit will be reviewed and graded by the investigator according to the CoFAR grading system. For one year following IFE
Secondary Rate of treatment failure Subject which stop daily ingestion of food treatment mix, prior to achieving study maintenance dose, for a period of 14 days or more At any time during the 12-month OIT phase
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Phase 2
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A